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Abstract: Water-insoluble glucan was isolated from the baker’s yeast Saccharomyces 
cerevisiae. The yeast cells were treated with alkali and the residue then with acid. 
Chemical and NMR (1D and 2D) analyses showed that a linear (1→3)-β-glucan was 
purified that was not contaminated with other carbohydrates, proteins or phenolic 
compounds. The effects of the glucan on wound healing were assessed in human venous 
ulcers by histopathological analysis after 30 days of topical treatment. (1→3)-β-glucan 
enhanced ulcer healing and increased epithelial hyperplasia, as well as increased 
inflammatory cells, angiogenesis and fibroblast proliferation. In one patient who had an 
ulcer that would not heal for over 15 years, glucan treatment caused a 67.8% decrease in 
the area of the ulcer. This is the first study to investigate the effects of (1→3)-β-glucan on 
venous ulcer healing in humans; our findings suggest that this glucan is a potential natural 
biological response modifier in wound healing. 
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1. Introduction 
Wound healing is an extremely complex biological process that is regulated by molecular and 
cellular events to promote tissue repair. Wound healing requires the proliferation, differentiation and 
recruitment of numerous cell types, including keratinocytes, endothelial cells, fibroblasts and immune 
cells, such as neutrophils, monocytes/macrophages, lymphocytes and dendritic cells [1]. 
After an injury, a platelet plug is formed that is surrounded by a fibrin matrix, which becomes a 
scaffold for infiltrating cells to adhere. During the early stage, recruited neutrophils phagocytose and 
degrade the devitalized tissue and release pro-inflammatory cytokines, such as interleukin-1β (IL-1β), 
interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). These cytokines are essential for the 
activation of keratinocytes, fibroblasts and additional cells [2,3]. Subsequently, monocytes migrate to 
the wound and differentiate into macrophages. The macrophages act similarly to the neutrophils and 
produce pro-inflammatory cytokines, as well as reactive oxygen and nitrogen intermediates, which 
play an important role in host defense. In addition, macrophages release growth factors, including 
platelet-derived growth factor (PDGF), transforming growth factor (TGF)-β, TGF-α, basic fibroblast 
growth factor (bFGF) and vascular endothelial growth factor (VEGF). These factors stimulate 
angiogenesis, stimulate extracellular matrix synthesis by local fibroblasts and promote granulation 
tissue formation and reepithelialization [4–6]. 
During wound healing, T-lymphocytes produce growth factors and function as immunological 
effector cells, which play a role in the activation of macrophages and B-lymphocytes. T-lymphocytes 
also function as regulatory cells and control the proliferation phase of wound healing. B-lymphocytes 
have several essential functions that regulate the immune response, including cytokine, growth factors 
and immunoglobulin production, as well as antigen presentation and regulation of T-lymphocyte 
activation and differentiation [7,8]. Nevertheless, the healing process can occur very slowly in some 
instances and the wound has an increased risk of becoming contaminated and infected. Thus, several 
Int. J. Mol. Sci. 2012, 13 8144 
 
research groups have sought to identify molecules from natural sources that can accelerate wound 
healing, such as glucans. 
Glucans are glucose polymers with an α- or β-type glycosidic chain. Glucans are present in fungi, 
plants, algae and bacteria. In fungi, β-glucans are the major components of the cell wall and are usually 
linked to proteins, lipids and other polysaccharides, such as mannan [9]. One major source of β-glucan 
is the baker’s yeast Saccharomyces cerevisiae. In this yeast, β-glucans primarily exist in the  
(1→3)-β-linked backbone form with (1→6)-β-branches [10]. However, a minor amount of  
(1→3)-β-glucan also exists [11].  
The β-glucans are recognized as pathogen-associated molecular patterns (PAMPs) by several 
mammalian immune cell receptors, such as dectin-1, toll-like receptors, complement receptor 3 (CR3) 
and lactosylceramide. These receptors allow the β-glucan to interact with immune cells, such as 
neutrophils, macrophages and lymphocytes. These interactions activate several intracellular pathways 
that are responsible for the immunopharmacological properties of β-glucan; however, the complete 
mechanism β-glucan function is not yet fully understood [12]. 
In addition to interacting with immune cells, β-glucan also interacts with fibroblasts. Wei et al. [13] 
reported that (1→3)-β-glucan directly stimulated collagen biosynthesis in normal human dermal 
fibroblasts by activating two families of transcription factors, activator protein 1 (AP-1) and specific 
protein 1 (SP-1).  
This polysaccharide has also been reported to increase wound healing in animals subjected to skin 
incision, colon anastomosis and burns. Depending on the route of administration, β-glucan enhanced 
wound healing by increasing macrophage infiltration and collagen deposition, by stimulating tissue 
granulation and by promoting reepithelialization [14–16]. Only one human wound healing study has 
been performed [17]. In this study, the authors demonstrated that (1→3),(1→6)-β-glucan was effective 
as a topical treatment for partial thickness burns in pediatric patients. However, there are no reports on 
the application of (1→3)-β-glucan in human wound healing.  
Venous ulcers are cutaneous wounds that result from chronic venous insufficiency; they are 
responsible for approximately 80%–85% of all ulcers that occur on the lower limbs. Venous ulcers 
represent a serious public health problem throughout the world. These wounds are difficult to heal 
because of their recurrence, high risk of infection and the high cost of treatment. These ulcers cause 
significant morbidity, pain, work productivity loss and decrease the quality of life in affected  
patients [18].  
Based on these considerations, the purpose of this study was to purify water-insoluble  
(1→3)-β-glucan, assess its chemical structure and evaluate its effect on venous ulcer healing  
in humans. 
2. Results and Discussion 
2.1. Structural Characterization  
Chemical analysis indicated that the extracted polysaccharide was composed solely of glucose. 
Proteins and phenolic compounds were not detected in the sample, which indicates that we 
successfully purified a homoglucan from S. cerevisiae. 
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The 13C NMR spectrum of the water-insoluble glucan showed six carbon signals at ∂ 102.86 (C-1) 
ppm, which correspond to β anomeric carbons, as well as at ∂ 85.96 (C-3), 76.27 (C-5), 72.94 (C-2), 
68.41 (C-4) and 60.91 (C-6) ppm (Figure 1A). This indicates that the polysaccharide contains 
homogeneous repeat monosaccharide units. Furthermore, the 13C NMR spectrum revealed no evidence 
of α anomeric configuration. Confirmation of free carbon 6 (C6) at ∂ 60.91 ppm was established by the 
inverted CH2 signal in DEPT-135 13C NMR (Figure 1B). 
Figure 1. 13C NMR spectrum of the water-insoluble glucan isolated from the baker’s yeast 
Saccharomyces cerevisiae. (A) The number of carbon atoms was labeled on each peak to 
indicate the position.  (B) The inset shows a DEPT-135 analysis of the C-6 region. 
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All of the protons were assigned to carbons using the two-dimensional (2D) 1H-13C NMR 
heteronuclear single quantum correlation (HSQC) spectrum (Table 1 and Figure 2). All of the NMR 
chemical shifts are comparable to literature values [19–23]. The results from the 1H-13C NMR 
spectrum confirmed that the water-insoluble compound is a (1→3)-β-linked glucan that is similar to 
laminarin, which is a standard (1→3)-β-glucan [24].  
Table 1. The assignments of 13C NMR and HSQC spectrum. 
Sugar Residue 
13C/1H (ppm) 
Ref. 
1 2 3 4 5 
6 
6a 6b 
→3)-β-Glc-(1→ 102.85 72.94 85.95 68.41 76.26 60.91  a 
4.53 3.32 3.50 3.27 3.27 3.71 3.49 
→3)-β-Glc-(1→ 102.49 72.46 85.76 68.18 76.02 60.67  b 
4.55 3.34 3.51 3.31 3.31 3.74 3.51 
→6)-β-Glc-(1→ 104.66 74.71 76.57 71.14 77.25 70.48  c 
4.42 3.22 3.40 3.35 3.53 4.12 3.75 
→3,6)-β-Glc-(1→ 102.96 73.04 85.76 68.53 74.96 68.68  d 
4.54 3.34 3.54 3.26 3.52 4.08 3.58 
→3,4)-β-Glc-(1→ 103.02 73.69 85.34 68.99 76.48 61.97  e 
- - - - - -  
a: This work; b: Freimund et al. [21]; c: Bi et al. [19] ; d: Tada et al. [23]; e: Roubroeks et al. [22]. 
Figure 2. 1H and 13C HSQC spectra of the water-insoluble glucan isolated from the baker's 
yeast Saccharomyces cerevisiae. The 13C NMR and 1H NMR spectra are displayed on the 
vertical and horizontal axes, respectively. 
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Linear (1→3)-β-glucans are present in several microorganisms, such as in the capsular 
polysaccharides of gram-negative bacteria that belong to the rhizobiaceae (e.g., the Agrobacterium sp.) [25] 
the gram-positive bacteria Cellulomonas flavigena [26] and the sclerotia of the basidiomycete fungus 
Poria cocos [27]. In S. cerevisiae, (1→3),(1→6)-β-glucan, which comprises approximately 50% of the 
cell wall, forms a core where the non-reducing termini are covalently linked either to chitin, (1→6)-β-glucan 
or mannoprotein, which together compose approximately 40% of the wall. Minor amounts of  
(1→3)-β-glucan are additionally present in S. cerevisiae [11]. 
In this work, we isolated (1→3)-β-glucan from S. cerevisiae. The purified glucan was not 
contaminated with other carbohydrates, proteins or phenolic compounds, which has been historically 
difficult to achieve. Because there have been few studies that have assessed the biological activity of 
this glucan, and because there are no reports that have assessed the effect of (1→3)-β-glucan on 
venous ulcer healing in animals or humans, we sought to purify the compound and assess its effect on 
human ulcer wound healing. 
2.2. Study Subjects 
We followed 12 patients who had venous ulcers; within this study group, 1 patient had 2 ulcers. 
Nine patients (75%) were women and three (25%) were men. The patient age ranged from 42 to 75, 
with an average of 59 +/− 10.5 years.  
Topical immunotherapy was applied to 13 venous ulcers, of which 9 (69.2%) were located in the 
middle third of the leg. The average ulcer lifespan was 142.9 months (range of 8 to 264 months) and 
the majority of the ulcers (61.5%) were recurrent wounds.  
In all of the patients, the ulcers were associated with chronic venous insufficiency. The patients had 
careers that favored venous stasis where they remained seated or standing for prolonged time periods. 
In addition, 6 (50%) patients had hypertension, of whom 3 (25%) also had diabetes mellitus. These 
factors probably cooperated in the development of nonhealing venous ulcers. 
2.3. Tissue Sample Collection and Histopathological Analysis  
For the qualitative histopathological analysis, 13 ulcer biopsy fragments were evaluated before 
therapy initiation (day 0) and 13 fragments were evaluated on day 30 of glucan treatment, for a total of 
26 fragments. In addition, the number of lymphocytes, plasmocytes and neutrophils were determinate.  
Epithelial hyperplasia was present at the ulcer edges in all of the specimens at day 0. Five 
specimens (38.5%) had reactive and reparative epithelial changes in the stratified squamous epithelium 
that were associated with hyperplasia. Keratinocyte reactivity was clearly demonstrated by the 
presence of anisokaryosis, anisonucleose and other changes. Inflammation was apparent in all of the 
specimens and inflammatory cells: lymphocytes (mean: 25.62 cells/field), plasmocytes (mean:  
25.23 cells/field) and neutrophils (mean: 43.31 cells/field) were present.  
Angiogenesis was present in 100% of the specimens at day 0. Well-formed vessels with a  
well-defined thickness and edema were observed. Fibroblast proliferation and collagen fibrosis were 
detected in all of the specimens. Senescent fibroblasts were present in the ulcer margin and there was a 
predominance of new fibroblasts in the ulcerated area. The collagen fibers on the ulcer edges were 
well formed and had a homogeneous distribution pattern. The collagen fibers in the ulcerated area 
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were delicate and were distributed in the upper dermis. For the remaining two-thirds of dermis, there 
was a dense distribution of fibers that was associated with inflammation and edema (Figures 3 and 4). 
New biopsies were taken after 30 days of glucan treatment. By day 30, histopathology indicated 
that there was an increase in epithelial hyperplasia. Additionally, 12 specimens (92.3%) had reactive 
and reparative epithelial changes of the stratified squamous epithelium that were associated with 
hyperplasia, of which 2 (15.4%) specimens had reepithelialization zones that covered the previously 
denuded areas. These data suggest that an increase in epithelial cell migration occurred.  
Inflammation was present in all of the samples and was identified an increase in the number of 
inflammatory cells: lymphocytes (mean: 31.23 cells/field), plasmocytes: (mean: 42.85 cells/field) and 
neutrophils: (44.54 cells/field). The differences between the number of inflammatory cells before 
therapy initiation (day 0) and after 30 days of glucan treatment (day 30) were evaluated and the 
increase in the number of plasmocytes was statistically significant (p = 0.018). The number of 
inflammatory cells may have been influenced by the ability of the glucan to promote cell proliferation 
in local ulcerated regions and subsequential leukocyte recruitment. As previously described, 
leukocytes are essential for the production of growth factors, cytokines and other inflammatory 
mediators that play a key role in wound healing and host defense.  
Figure 3. Histology of the venous ulcers. The tissue was stained with hematoxylin and 
eosin (H & E) to visualize the cellular morphology. Samples A, B and C were collected 
prior to (1→3)-β-glucan treatment. The following magnifications are shown: 100 × H & E 
stain for A; 400 × H & E stain for B and C. (A) The arrow indicates epithelial hyperplasia 
at the edge of the ulcer. (B) Arrow No. 1 shows reactive and reparative epithelial changes 
in the stratified squamous epithelium and the other arrows show inflammatory cell 
infiltration, including neutrophil (arrow No. 2), plasmocyte (arrow No. 3) and lymphocyte 
(arrow No. 4). (C) Arrow No. 1 indicates angiogenesis associated with edema and arrow 
No. 2 indicates fibroblast.  
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Figure 3. Cont. 
 
 
Angiogenesis was present in 100% of the specimens and maintained the same pattern before and 
after glucan treatment. Fibroblast proliferation was observed in 100% of the specimens and the number 
of fibroblasts was higher on day 30 compared to day 0. Additionally, there were senescent fibroblasts 
in the sample margin and an increased number of new fibroblasts in the ulcerated area. Collagen 
fibrosis was present in the same pattern at day 30 compared to day 0 (Figures 3 and 4). Fibroblasts 
contribute to granulation tissue formation by synthesizing collagen, elastin, fibronectin, 
glycosaminoglycan and proteases (components of extracellular matrix). They also produce cytokines 
that promote keratinocyte proliferation and migration and promote myofibroblast differentiation to 
promote wound closure [1].  
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Figure 4. Venous ulcer histology. The tissues in samples A and B were stained with 
Masson’s trichrome, while sample C was stained with picrosirius red. Samples A, B and C 
were obtained prior to (1→3)-β-glucan treatment. The magnifications shown are as 
follows: 100 × for samples A and C; 400 × for sample B. (A and C) Arrow No. 1 indicates 
new collagen deposition in the ulcerated area and arrow No. 2 indicates senescent collagen 
deposition deep within then venous ulcer. (B) Arrow No. 1 indicates senescent fibroblast 
and arrow No. 2 indicates young fibroblast amid collagen deposition in the ulcerated area. 
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Figure 4. Cont. 
 
The current standard of treatment for chronic venous ulcers is the application of compression 
bandages to reduce venous pressure and edema as well as to improve venous return [28,29]. However, 
venous ulcers do not always heal in response to the standard therapies, especially ulcers that have 
persisted for long periods of time or reoccur.  
Experimental studies with other wounds types have reported that topical or systemic β-glucan 
administration enhances wound healing. Leibovich and Danon (1980) [30] reported that there was a 
higher number of macrophages in the early inflammatory stage of repair. In mice, reepithelialization 
and the onset of fibroplasias commenced at an earlier stage when (1→3)-β-glucan was topically 
applied to the wound compared with the control group. Topical application of (1→3)-β-glucan to 
wounds in mice, rats and guinea pigs accelerated reepithelialization and increased fibroblast 
proliferation and fibrogenesis by activating macrophages [31]. In another study, (1→3)-β-glucan was 
administered intravenously and topically in rats that had dorsal skin incisions; treatment enhanced 
macrophage function and increased the early wound strength, which may have been strengthened by 
increased collagen cross-linking [32]. 
Portera et al. [33] reported that macrophage modulation via intravenous administration of (1→3)-β-glucan 
phosphate increased tensile strength in experimental colon anastomosis and skin incisions in rodents. 
Additionally, they observed a positive correlation between phosphate (1→3)-β-glucan treatment, 
wound tensile strength and collagen biosynthesis.  
Artificial skin, which was obtained from cultured fibroblasts and keratinocytes in a medium 
containing (1→3),(1→6)-β-glucan and gelatin, was applied to experimentally induced wounds in 
athymic mice and promoted reepithelialization [15]. 
Toklu et al. [16] reported that local and oral administration of (1→3),(1→6)-β-glucan protected 
against burn-induced oxidative tissue damage in rats. Topical application of aminated (1→3)-β-glucan 
(AG) improved wound healing in mice with diabetes mellitus and histologic examinations of the 
wounds revealed vascularized granulation tissue that was rich in cells and had increased 
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reepithelialization compared with the placebo group [14]. Delatte et al. [17] reported that 
(1→3),(1→6)-β-glucan associated with collagen matrix was an effective treatment that significantly 
decreased post-injury pain in partial thickness burns in pediatric patients.  
2.4. Ulcer Area Imaging and Measurement 
Initially, the venous ulcers possessed an average area of 27.51 cm2 (range of 8.38 to 66.89 cm2). 
Although these wounds were difficult to heal because of their duration, recurrence and area, the 
average of the reduction percentage on ulcer area was 11.3% after 30 days of glucan treatment. By day 
90, one venous ulcer had healed completely, and 7 ulcers exhibited an average area of 16.48 cm2 
(range of 2.08 to 41.42 cm2); the average of the reduction percentage on ulcer area was 55.23% at day 
90. Figure 5A–D shows a venous ulcer on a right leg that healed completely after 90 days of glucan 
treatment. Interestingly, the ulcer shown in Figure 5E–H, which has not healed over the past 15 years, 
reduced in size by 67.8% after only 3 months of glucan treatment. 
Figure 5. Ulcer healing over time with (1→3)-β-glucan treatment. The images represent 
the progress of ulcer healing over the treatment time course for 2 patients. (A) A venous 
ulcer in the right leg at day 0 that measures 8.38 cm2. (B) The venous ulcer shown in (A) at 
day 30, which measures 4.84 cm2. (C) The venous ulcer shown in (A) at day 60, which 
measures 2.92 cm2. (D) The venous ulcer shown in (A) at day 90, which has completely 
healed. (E) A venous ulcer on the left foot at day 0 that measures 27.3 cm2. (F) The venous 
ulcer shown in (E) at day 30, which measures 25.62 cm2. (F) The venous ulcer shown in 
(E) at day 60, which measures 15.87 cm2. (H) The venous ulcer shown in (E) at day 90, 
which measures 8.78 cm2. 
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3. Experimental Section 
3.1. Materials  
Sodium hydroxide (NaOH), hydrochloric acid (HCl), 99.8% ethyl alcohol (EtOH), hematoxylin and 
eosin yellow were purchased from Vetec® (Rio de Janeiro, Brazil). S. cerevisiae (baker’s yeast) was 
purchased from Fleischmann® (Rio de Janeiro, Brazil). All the other reagents used in this work were 
analytical grade. 
3.2. Isolation of Water-Insoluble (1→3)-β-Glucan 
Water-insoluble (1→3)-β-glucan was isolated from S. cerevisiae. The yeast cells were treated with 
alkali and the residue then with acid at the Laboratory of Clinical Immunology, UFRN according to 
the method described by Hassid et al. [34] with some modifications. Briefly, 1.5 kg of dry yeast was 
digested in 3% NaOH (2 L) at 80 °C for 6 hours and then incubated at room temperature overnight. 
The supernatant was discarded and the extraction was repeated. The residue was subsequently 
acidified with approximately 2.8 L of 4 M HCl and digested for several hours at 80 °C. After the 
digested mixture was incubated overnight at room temperature, the supernatant was discarded and the 
residue was subjected to a new digestion with 3% HCl (2 L). The overall yield was approximately 40 g. 
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3.3. Structural Characterization 
The total sugar concentration was estimated with a phenol-H2SO4 reaction [35] with D-glucose as 
the standard. The total protein concentration was measured with the Bradford method [36] using 
bovine serum albumin (BSA) as the standard. The total phenolic compound concentration was 
determined by the Folin-Ciocalteu colorimetric method using gallic acid as the standard [37]. The 
polymers were hydrolyzed (5 M TCA, 100 °C, 2 h) and the sugar composition was determined by high 
performance liquid chromatography (HPLC) (Merck Hitachi Elite LaChrom®) on a machine equipped 
with a refractive index detector and a LichroCART® 250-4 column. Arabinose, galactose, glucose, 
fucose, mannose, rhamnose and xylose were used for references. 
The β-glucan (50 mg) was dissolved in 800 µL of DMSO-d6. Nuclear magnetic resonance (NMR) 
spectra (13C and DEPT-135) were obtained with a 400 MHz Bruker Avance III spectrometer in an 
inverse 5 mm gradient probe head at 70 °C. 1H-13C NMR heteronuclear single quantum correlation 
(HSQC) spectra were recorded using states-times proportion phase incrementation for quadrature 
detection in the indirect dimension. The HSQC spectra were performed with 1024 × 256 points and 
globally optimized and alternating-phase rectangular pulses for decoupling were applied. The chemical 
shifts are expressed in δ relative to acetone at δ 32.77 (13C) and 2.21 (1H), based on sodium  
2,2-dimethyl-2-silapentane-3,3,4,4,5,5-d6-5-sulfonate (DSS) at δ = 0.00 for 13C and 1H in accordance 
with IUPAC recommendations.  
3.4. Study Subjects 
A nonrandomized clinical trial with intragroup comparisons over time was performed. The study 
was approved by the Research Ethics Committee of the University Hospital Onofre Lopes, 
HUOL/UFRN, Brazil (protocol number: 147/07). The study included male and female venous ulcer 
patients who were older than 18. The patients were admitted to the Vascular Surgery Ambulatory at 
the University Hospital Onofre Lopes, HUOL/UFRN. The exclusion criteria were the following: 
autoimmune disease, heart, renal or liver insufficiency and/or malignancies. Data regarding the ulcer 
location, duration, status (new or recurrent) and surface area were collected. The baseline patient 
medical history information included the following: diabetes mellitus, hypertension, endocrine disease, 
peripheral vascular disease, connective tissue disease, musculoskeletal disease and neurological disorders. 
3.5. (1→3)-β-Glucan Treatment 
Powdered (1→3)-β-glucan was autoclaved and dispersed in cream with crodabase CR2 to a final 
concentration of 3%; the cream was applied directly to the ulcer bed after the area was cleaned with a 
0.9% sterile saline solution. The ulcers were subsequently covered with nonadherent gauze, moistened 
with 0.9% sterile saline and covered with a crepe bandage. This procedure was performed daily for up 
to 90 days. 
3.6. Tissue Sample Collection and Histopathological Analysis  
A venous ulcer biopsy was taken from all of the patients before therapy initiation (day 0) and after 
30 days of glucan treatment (day 30). Prior to tissue sample collection, 2% xylocaine was injected for 
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local anesthesia. The biopsy was extracted with a n° 15 blade scalpel and included the ulcerated area 
and the ulcer edge. The tissue was fixed in 10% formalin for 24 hours, processed according to the 
Laboratory of Pathology/UFRN protocol and stained with hematoxylin and eosin to visualize the skin 
structure, as well as the cellular and tissue components. The tissue was also stained with Masson’s 
trichrome and picrosirius red to identify the collagen fibers. The following parameters were assessed 
for the histopathological analyses: epithelial hyperplasia, inflammatory response, angiogenesis, 
fibroblast proliferation and collagen fibrosis. Histomorphometric analysis of inflammatory cells 
(neutrophils, lymphocytes and plasmocytes) was performed and 7 microscopic high power fields per 
specimen were counted (magnification 400×). The number of inflammatory cells in each field was 
counted and the mean of all fields was calculated. The differences between the number of 
inflammatory cells before therapy initiation (day 0) and after 30 days of glucan treatment (day 30) 
were evaluated by the Wilcoxon test. p < 0.05 was considered statistically significant. 
3.7. Ulcer Imaging and Quantification of the Ulcer Area  
To monitor the healing progress, color images were acquired and the ulcer area was quantified with 
a computer program (AutoCAD 2008®) from a traced outline of the venous ulcer on transparent film. 
These procedures were performed before the initiation of therapy (day 0) and once every week for up 
to 90 days.  
4. Conclusions 
We purified a linear (1→3)-β-glucan from Saccharomyces cerevisiae using the method described 
by Hassid et al. [34]. (1→3)-β-glucan enhanced venous ulcer healing and increased epithelial 
hyperplasia, as well as increased the number of plasmocytes and fibroblast proliferation. This is the 
first study that investigated the effect of (1→3)-β-glucan in venous ulcer healing in humans; our 
findings suggest that this glucan is a potential natural biological response modifier for wound healing. 
Further studies are needed to assess the therapeutic benefits of this compound and to elucidate with 
more details the mechanisms responsible for wound healing. 
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